{"entity":{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","aka":["Evopoint Biosciences Inc."],"tldr":"Evopoint Biosciences is a China-based biotechnology company running 6 late-stage cancer trials of XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma and prostate cancer.","summary":"Evopoint Biosciences, based in Suzhou, China, is a biotechnology company. An innovation-focused pharmaceutical company (Chinese name Suzhou Innovent... registered as Suzhou Xinnuowei Pharmaceutical Technology Co.) developing small-molecule and antibody drugs for precision oncology and multi-drug resistant bacterial infections, using in-house small molecule, complex antibody (eMAB) and targeted protein degradation (eGLUE) platforms. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing XNW29016, XNW5004 and XNW28012 in peripheral T-cell lymphomas, follicular lymphoma, prostate cancer, hodgkin lymphoma and pancreatic ductal adenocarcinoma. The largest, NCT06799637 (Study of XNW28012 in Subjects With Advanced Solid Tumours Who Failed Standard Treatments), plans to enrol 350 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.evopointbio.com"},{"label":"ClinicalTrials.gov: trials led by Evopoint Biosciences","url":"https://clinicaltrials.gov/search?lead=Evopoint%20Biosciences%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["peripheral-t-cell-lymphoma","follicular-lymphoma","prostate","hodgkin-lymphoma","pancreatic","ovarian","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["xnw5004"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07545603","nct07730515","nct06702995","nct06776952","nct06799637","nct07823049","nct06987500"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Suzhou","country":"CN","companyType":"biotech","website":"https://www.evopointbio.com","investors":[],"funding":[]},"route":"/companies/evopoint-biosciences/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"xnw5004","kind":"drug","name":"XNW5004","route":"/drugs/xnw5004/"}],"trial":[{"id":"nct06776952","kind":"trial","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06776952/"},{"id":"nct06987500","kind":"trial","name":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","route":"/trials/nct06987500/"},{"id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/"},{"id":"nct07545603","kind":"trial","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","route":"/trials/nct07545603/"},{"id":"nct06799637","kind":"trial","name":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","route":"/trials/nct06799637/"},{"id":"nct07823049","kind":"trial","name":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy","route":"/trials/nct07823049/"},{"id":"nct06702995","kind":"trial","name":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06702995/"}]}}